• ADC Therapeutics SA ADCT.N reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of six analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -55 cents to -32 cents per share.

• Revenue rose 27.4% to $18.46 million from a year ago; analysts expected $18.46 million.

• ADC Therapeutics SA's reported EPS for the quarter was a loss of 42 cents​.

• The company reported a quarterly loss of $43.97 million.

• ADC Therapeutics SA shares had fallen by 7.0% this quarter and gained 76.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for ADC Therapeutics SA is 9.00

This summary was machine generated from LSEG data November 8 at 09:48 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)